Integra Lifesciences Holdings (IART) Research & Development (2009 - 2026)

Integra Lifesciences Holdings (IART) has 18 years of Research & Development data on file, last reported at $23.5 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 4.96% year-over-year to $23.5 million; the trailing twelve-month figure through Mar 2026 stood at $97.7 million (down 13.61% YoY), and the FY2025 full-year result was $99.0 million, down 14.22% from the prior year.
• Research & Development slipped to $23.5 million in Q1 2026, from $24.8 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $31.2 million in Q4 2024 to a low of $22.5 million in Q3 2025.
• A 5-year average of $26.1 million and a median of $26.6 million in 2023 frame the typical range for Research & Development.
• Across the five-year window, Research & Development climbed 28.52% in 2024 and retreated 20.57% in 2025, its largest moves.
• Tracing IART's Research & Development over 5 years: stood at $26.8 million in 2022, then dropped by 9.33% to $24.3 million in 2023, then increased by 28.52% to $31.2 million in 2024, then retreated by 20.57% to $24.8 million in 2025, then slipped by 5.2% to $23.5 million in 2026.
• Business Quant data shows IART's Research & Development at $23.5 million in Q1 2026, $24.8 million in Q4 2025, and $22.5 million in Q3 2025.